Bio-Rad Introduces Liquichek Serum Indices to Monitor an Instrument's Response to Detect HIL Specimen Interferences

Date: 
2019-01-29

Press Release

Bio-Rad Introduces Liquichek Serum Indices to Monitor an Instrument's Response to Detect HIL Specimen Interferences

HERCULES, Calif.–January 29, 2019 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced the availability of Liquichek Serum Indices that are used as part of laboratory interference testing to monitor an instrument’s ability to detect Hemolysis, Icterus, and Lipemia (HIL) specimen interferences in patient samples.

HIL interferences, originating from substances found in patient samples, can directly alter an assay result and contribute to pre-analytical variation that affects clinical chemistry testing. Liquichek Serum Indices is prepared from human-sourced material that resembles patient samples at HIL relevant concentrations and may provide laboratory technicians with confidence in their instrument's ability to detect HIL interferences in a patient sample.

Manual HIL interference detection involves subjective visual assessment from a trained laboratory technician and may result in longer turnaround times, errors, or require repeat testing. Utilizing the automated HIL detection feature on an instrument combined with Liquichek Serum Indices may help reduce errors by eliminating the need for manual inspection by a laboratory technician.

The Unity QC Data Management Solutions and Unity Interlaboratory Program, designed to improve the effectiveness of the laboratory’s statistical process control and monitor instrument performance among peer groups, is available for use with Liquichek Serum Indices.

Liquichek Serum Indices is an unassayed product that monitors instrument's response in detecting HIL interferences. For more information, please visit: www.qcnet.com/serumindices.


About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Radnobr> had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio rad.com.


This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “will”, “believe,” “expect,” “anticipate,” “may,” “plan,” “intend,” “estimate,” “offers,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


Press contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com